Valproic acid therapy in childhood epilepsy

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Epilepsy is a common neurological disorder in children.
• Effective seizure control and management of associated comorbidities are critical.
• Valproic acid is a widely used anticonvulsant, but its efficacy and safety profile in pediatric populations require ongoing evaluation.

Purpose of the Study:

• To evaluate the efficacy of valproic acid in improving seizure control in children with epilepsy.
• To assess the impact of valproic acid on alertness and behavior in pediatric patients.
• To document the incidence and nature of adverse effects associated with valproic acid treatment in children.

Main Methods:

• A cohort of 100 children with epilepsy received valproic acid, either as monotherapy or in combination with other anticonvulsants.
• Seizure control was assessed across different age groups and seizure types.
• Adverse events, including laboratory abnormalities and clinical side effects, were systematically recorded.

Main Results:

• Valproic acid demonstrated significant seizure control improvement, averaging 82%, across all pediatric age groups.
• Petit mal seizures showed the best response, but other seizure types, including those in children with cognitive impairments, also improved.
• Improvements in alertness and behavior were frequently observed alongside seizure control.
• Common transient side effects included leukopenia (27%) and elevated SGOT (44%).
• Less frequent adverse events included alopecia, gastrointestinal distress, pancreatitis, thrombocytopenia, edema, and coma.
• Three deaths occurred in severely impaired children, though causality with valproic acid remains unclear.

Conclusions:

• Valproic acid is an effective treatment for improving seizure control in children with epilepsy, with benefits extending to behavior and alertness.
• While generally well-tolerated, careful monitoring for potential toxic effects and drug interactions is essential during treatment.
• The study highlights the need for vigilant patient management to optimize therapeutic outcomes and mitigate risks in pediatric epilepsy care.